Radioimmunotherapy (RIT) is a rapidly expanding field and offers a new treatment for patients with advanced lymphoma. The group is committed to translational work in developing RIT for clinical applications. We have been able to demonstrate the ability of targeted irradiation and certain signalling mAb to work synergistically against tumour and we believe the principles learned have important implications for the selection of reagents for RIT of B-cell lymphoma. Preclinical lymphoma models are used to elucidate the mechanisms by which RIT treatment may be operating in vivo and we are starting to apply the results of these experiments with novel sequencing of RIT in treatment protocols in the clinic.

Current research focuses on the integration of chemotherapy with RIT, irradiation with anti-CD40 and the roles of CD4/CD8 effector cells in successful eradication of lymphoma. The experimental work is done in collaboration with Professor Martin Glennie and Professor Peter Johnson. A busy clinical RIT research program exists alongside the laboratory work and this is done in conjunction with Dr Val Lewington (Director of Nuclear Medicine), Dr Kim Orchard (Director of Regional Transplantation). A wide range of relapsed "indolent" and "aggressive" non Hodgkin's lymphoma are treated with Yttrium-90 and Iodine-131 labelled anti-CD20 conjugates.